Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

German life science part two: difficult times, unusual strat...

In part two, Mariana Brea-Krueger discusses new strategies that biotech and pharma will need to consider in order to survive the current pricing squeeze. Germany leads the way in new legislation to curb cost in its national health insurance system (GKV). Demographically, the aging...

Articles

Spotlight on... HIV and AIDS

This month’s spotlight is on HIV and AIDS – we speak with Dr Michael Brady to find out how pharma and the UK government are supporting patients in this disease area. By the end of 2010, an estimated 34 million people were living with HIV worldwide – up 17% from the...

Articles

Medicines adherence – the forgotten role of pharma marketing...

New data suggests that poor medicines adherence costs pharma over $500 billion per annum, so Atlantis Healthcare spoke to a number of stakeholders to identify some solutions. With the publication of the recent IMS Institute for Healthcare Informatics report entitled ‘Advancing the responsible use of medicines’ stating that annual savings of…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital